Wang Zili, Wang Xudong, Liao Yidong, Chen Guangtang, Xu Kaya
Department of Neurosurgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
School of Clinical Medicine, Guizhou Medical University, Guiyang, China.
Front Neurol. 2022 Sep 20;13:991379. doi: 10.3389/fneur.2022.991379. eCollection 2022.
Stroke is a leading cause of death and long-term disability worldwide. Tissue plasminogen activator (tPA) is an effective treatment for ischemic stroke. However, only a small part of patients could benefit from it. Therefore, finding a new treatment is necessary. Bone marrow mesenchymal stromal cells (BMSCs) provide a novel strategy for stroke patients. Now, many patients take stem cells to treat stroke. However, the researches of the precise inflammatory mechanism of cell replacement treatment are still rare. In this review, we summarize the immune response of BMSCs treated to stroke and may provide a new perspective for stem cell therapy.
中风是全球范围内导致死亡和长期残疾的主要原因。组织型纤溶酶原激活剂（tPA）是缺血性中风的有效治疗方法。然而，只有一小部分患者能从中受益。因此，寻找新的治疗方法很有必要。骨髓间充质基质细胞（BMSCs）为中风患者提供了一种新策略。现在，许多患者采用干细胞治疗中风。然而，关于细胞替代治疗的确切炎症机制的研究仍然很少。在这篇综述中，我们总结了BMSCs治疗中风的免疫反应，可能为干细胞治疗提供新的视角。
